相关实验视频

Updated: Jun 25, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

作为癌症点的SETDB1:药物设计中的挑战和前景

Haifa Hassanie¹, André Berndt Penteado¹, Larissa Costa de Almeida²

¹School of Pharmaceutical Sciences, University of São Paulo Brazil trossini@usp.br.

RSC medicinal chemistry

|May 27, 2024

概括

基因组的稳定性依赖于染色质动态,这对于预防癌症至关重要. 向SET域的双分色素甲基转移酶1 (SETDB1) 提供了针对癌症进展和耐药性的新策略.

科学领域:

表观遗传学和分子生物学
癌症研究癌症研究
染色体生物学染色体生物学

背景情况:

基因组稳定性由染色质动力学调节,包括基因素修饰和依赖ATP的染色质重塑剂.
这些过程的失调与恶性瘤有关.
基因组修饰和染色质重塑之间的交叉对转录调节和细胞命运至关重要.

研究的目的:

为了审查SET域分叉的 histone lysine甲基转移酶1 (SETDB1) 在癌症中的作用.
讨论SETDB1在各种癌症中的过度表达及其对瘤进展的影响.
探索开发针对SETDB1进行癌症治疗的抑制剂药物.

主要方法:

文献综述侧重于SETDB1功能及其在致癌过程中的作用.
对人类癌症中SETDB1过度表达的研究分析.
讨论涉及SETDB1抑制的治疗策略.

主要成果:

SETDB1是一种参与 euchromatic 和 heterochromatic 标记的基因组 lysine 甲基转移酶.
SETDB1促进瘤抑制基因沉默,有助于致癌.
在多种癌症类型中观察到SETDB1过度表达,与增强的瘤生长和转移相关.

结论:

SETDB1是新型癌症治疗的重要表观遗传标.
向SETDB1可能有助于克服癌细胞对现有治疗方法的抗性.
进一步开发SETDB1抑制剂对于改善治疗结果至关重要.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...